Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
7,950.00
-300.00 (-3.64%)
Aug 12, 2026, 3:30 PM KST
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 324.68M KRW in the quarter ending March 31, 2026, a decrease of -54.19%. This brings the company's revenue in the last twelve months to 3.13B, down -70.74% year-over-year. In the year 2025, Hyundai Bioscience had annual revenue of 3.52B, down -76.63%.
Revenue (ttm)
3.13B
Revenue Growth
-70.74%
P/S Ratio
254.10
Revenue / Employee
45.41M
Employees
69
Market Cap
796.15B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.52B | -11.53B | -76.63% |
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.29T |
| Medy-Tox | 244.02B |
| MEDIPOST | 73.90B |
| Onconic Therapeutics | 67.20B |
| Pharmicell | 23.94B |
| GI Innovation | 5.63B |
| AbClon | 4.74B |